Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Biogen Inc. buy UBS Group AG

Start price
€249.60
24.07.23 / 50%
Target price
€302.51
24.07.24
Performance (%)
-16.51%
End price
€208.40
25.07.24
Summary
This prediction ended on 25.07.24 with a price of €208.40. The prediction for Biogen Inc. disappointed with a performance of -16.51%. UBS_Group_AG has a follow-up prediction for Biogen Inc. where he still thinks Biogen Inc. is a Buy. UBS_Group_AG has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Biogen Inc. 1.119% 1.119% -25.323%
iShares Core DAX® 1.560% 4.721% 18.671%
iShares Nasdaq 100 0.517% 1.171% 23.619%
iShares Nikkei 225® 1.730% 6.073% 16.253%
iShares S&P 500 1.482% 1.218% 23.290%

Comments by UBS_Group_AG for this prediction

In the thread Biogen Inc. diskutieren
Prediction Buy
Perf. (%) -16.51%
Target price 302.505
Change
Ends at 24.07.24

Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at UBS Group AG from $346.00 to $335.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat

In the thread Trading Biogen Inc.
Prediction Buy
Perf. (%) -16.51%
Target price 302.505
Change
Ends at 24.07.24

Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten

Current prediction by UBS_Group_AG for Biogen Inc.

buy
Biogen Inc.

Start price
Target price
Perf. (%)
€216.40
08.11.23
€291.35
08.11.24
-14.12%
15:49